Cargando…
Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand
Plasma Trimethylamine-N-oxide (TMAO), a gut microbiota metabolite from dietary phosphatidylcholine, is mechanistically linked to cardiovascular disease (CVD) and adverse cardiovascular events. We aimed to examine the relationship between plasma TMAO levels and subclinical myocardial damage using hig...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298599/ https://www.ncbi.nlm.nih.gov/pubmed/34294762 http://dx.doi.org/10.1038/s41598-021-93803-7 |
_version_ | 1783726098774753280 |
---|---|
author | Senthong, Vichai Kiatchoosakun, Songsak Wongvipaporn, Chaiyasith Phetcharaburanin, Jutarop Tatsanavivat, Pyatat Sritara, Piyamitr Phrommintikul, Arintaya |
author_facet | Senthong, Vichai Kiatchoosakun, Songsak Wongvipaporn, Chaiyasith Phetcharaburanin, Jutarop Tatsanavivat, Pyatat Sritara, Piyamitr Phrommintikul, Arintaya |
author_sort | Senthong, Vichai |
collection | PubMed |
description | Plasma Trimethylamine-N-oxide (TMAO), a gut microbiota metabolite from dietary phosphatidylcholine, is mechanistically linked to cardiovascular disease (CVD) and adverse cardiovascular events. We aimed to examine the relationship between plasma TMAO levels and subclinical myocardial damage using high-sensitivity cardiac troponin-T (hs-cTnT). We studied 134 patients for whom TMAO data were available from the Cohort Of patients at a high Risk of Cardiovascular Events—Thailand (CORE-Thailand) registry, including 123 (92%) patients with established atherosclerotic disease and 11 (8%) with multiple risk factors. Plasma TMAO was measured by NMR spectroscopy. In our study cohort (mean age 64 ± 8.9 years; 61% men), median TMAO was 3.81 μM (interquartile range [IQR] 2.89–5.50 μM), and median hs-cTnT was 15.65 ng/L (IQR 10.17–26.67). Older patients and those with diabetic or hypertension were more likely to have higher TMAO levels. Plasma TMAO levels correlated with those of hs-cTnT (r = 0.54; p < 0.0001) and were significantly higher in patients with subclinical myocardial damage (hs-cTnT ≥ 14 ng/L; 4.48 μM vs 2.98 μM p < 0.0001). After adjusting for traditional risk factors, elevated TMAO levels remained independently associated with subclinical myocardial damage (adjusted odds ratio [OR]: 1.58; 95% CI 1.24–2.08; p = 0.0007). This study demonstrated that plasma TMAO was an independent predictor for subclinical myocardial damage in this study population. |
format | Online Article Text |
id | pubmed-8298599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82985992021-07-27 Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand Senthong, Vichai Kiatchoosakun, Songsak Wongvipaporn, Chaiyasith Phetcharaburanin, Jutarop Tatsanavivat, Pyatat Sritara, Piyamitr Phrommintikul, Arintaya Sci Rep Article Plasma Trimethylamine-N-oxide (TMAO), a gut microbiota metabolite from dietary phosphatidylcholine, is mechanistically linked to cardiovascular disease (CVD) and adverse cardiovascular events. We aimed to examine the relationship between plasma TMAO levels and subclinical myocardial damage using high-sensitivity cardiac troponin-T (hs-cTnT). We studied 134 patients for whom TMAO data were available from the Cohort Of patients at a high Risk of Cardiovascular Events—Thailand (CORE-Thailand) registry, including 123 (92%) patients with established atherosclerotic disease and 11 (8%) with multiple risk factors. Plasma TMAO was measured by NMR spectroscopy. In our study cohort (mean age 64 ± 8.9 years; 61% men), median TMAO was 3.81 μM (interquartile range [IQR] 2.89–5.50 μM), and median hs-cTnT was 15.65 ng/L (IQR 10.17–26.67). Older patients and those with diabetic or hypertension were more likely to have higher TMAO levels. Plasma TMAO levels correlated with those of hs-cTnT (r = 0.54; p < 0.0001) and were significantly higher in patients with subclinical myocardial damage (hs-cTnT ≥ 14 ng/L; 4.48 μM vs 2.98 μM p < 0.0001). After adjusting for traditional risk factors, elevated TMAO levels remained independently associated with subclinical myocardial damage (adjusted odds ratio [OR]: 1.58; 95% CI 1.24–2.08; p = 0.0007). This study demonstrated that plasma TMAO was an independent predictor for subclinical myocardial damage in this study population. Nature Publishing Group UK 2021-07-22 /pmc/articles/PMC8298599/ /pubmed/34294762 http://dx.doi.org/10.1038/s41598-021-93803-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Senthong, Vichai Kiatchoosakun, Songsak Wongvipaporn, Chaiyasith Phetcharaburanin, Jutarop Tatsanavivat, Pyatat Sritara, Piyamitr Phrommintikul, Arintaya Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand |
title | Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand |
title_full | Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand |
title_fullStr | Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand |
title_full_unstemmed | Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand |
title_short | Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand |
title_sort | gut microbiota-generated metabolite, trimethylamine-n-oxide, and subclinical myocardial damage: a multicenter study from thailand |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298599/ https://www.ncbi.nlm.nih.gov/pubmed/34294762 http://dx.doi.org/10.1038/s41598-021-93803-7 |
work_keys_str_mv | AT senthongvichai gutmicrobiotageneratedmetabolitetrimethylaminenoxideandsubclinicalmyocardialdamageamulticenterstudyfromthailand AT kiatchoosakunsongsak gutmicrobiotageneratedmetabolitetrimethylaminenoxideandsubclinicalmyocardialdamageamulticenterstudyfromthailand AT wongvipapornchaiyasith gutmicrobiotageneratedmetabolitetrimethylaminenoxideandsubclinicalmyocardialdamageamulticenterstudyfromthailand AT phetcharaburaninjutarop gutmicrobiotageneratedmetabolitetrimethylaminenoxideandsubclinicalmyocardialdamageamulticenterstudyfromthailand AT tatsanavivatpyatat gutmicrobiotageneratedmetabolitetrimethylaminenoxideandsubclinicalmyocardialdamageamulticenterstudyfromthailand AT sritarapiyamitr gutmicrobiotageneratedmetabolitetrimethylaminenoxideandsubclinicalmyocardialdamageamulticenterstudyfromthailand AT phrommintikularintaya gutmicrobiotageneratedmetabolitetrimethylaminenoxideandsubclinicalmyocardialdamageamulticenterstudyfromthailand |